Ruesch Center | Georgetown University

Gastrointestinal (GI) Cancers are the most common and most fatal of all cancers. The Ruesch Center will re-focus national efforts on curing this deadly set of diseases.

Logo of the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center. This logo has four blue boxes and text.

Meet Ruesch Center Director:
John L. Marshall, MD

Connect With Us Via

Tweets by RueschCenter

Recent News

Immunotherapy Hype and Oncologists' Fear of Failure Drive 'Hail Mary' Treatments
June 14, 2018
John Marshall speaks with Leonard Saltz and Tanios Bekaii-Saab about the destructive trend of trying experimental drugs before having the data, and the new 'right to try' law.
Underuse of exon mutational analysis for gastrointestinal stromal tumors
June 7, 2018
Increased use of EMA will improve clinical outcomes in both current and future patients by informing treatment plans and identifying new, potential therapeutic targets as the role of genetics in medicine continues to expand.
Pancreatic Cancer Case Studies Case-Based Peer Perspectives > Pancreatic Cancer > Case Studies: Improving the Treatment of Locally Advanced Pancreatic Cancer
May 24, 2018
Expert John Marshall, MD, reviews the case of a 64-year-old woman who presents with locally advanced pancreatic adenocarcinoma and shares insight on optimal diagnostic workup and molecular analysis techniques.
Expert Highlights Long-Lasting Benefits of Pembrolizumab for Patients With GI Cancers
May 9, 2018
Pembrolizumab (Keytruda), for example, has induced durable responses in certain subsets of patients with gastric and colorectal cancer (CRC), but many patients still do not respond to this type of therapy.
Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers
May 3, 2018
Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
May 1, 2018
TML-high rate varied widely among gastrointestinal cancers. Although MSI is conceivably the main driver for TML-high, other factors may be involved.
Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer
May 1, 2018
Pancreatic ductal adenocarcinoma (PDAC) remains the most aggressive malignancy with the lowest 5-year survival rate of all cancers in part owing to the lack of tumor-specific therapy and the rapid metastatic nature of this cancer.
Immuno‐Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD‐L1 Testing May Not Be Enough
April 27, 2018
PD-L1 testing alone fails to detect patients who may benefit from ICI. Lower PD-L1 thresholds and TML testing should be considered in future clinical trials.

The Ruesch Center for the Cure of Gastrointestinal Cancers

About

Patients & Families

Living with Cancer

Education & Events

Healthcare Professionals

Newsroom

Gastrointestinal (GI) Cancers are the most common and most fatal of all cancers. The Ruesch Center will re-focus national efforts on curing this deadly set of diseases.

Immunotherapy Hype and Oncologists' Fear of Failure Drive 'Hail Mary' Treatments

Underuse of exon mutational analysis for gastrointestinal stromal tumors

Pancreatic Cancer Case Studies Case-Based Peer Perspectives > Pancreatic Cancer > Case Studies: Improving the Treatment of Locally Advanced Pancreatic Cancer

Expert Highlights Long-Lasting Benefits of Pembrolizumab for Patients With GI Cancers

Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer

Immuno‐Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD‐L1 Testing May Not Be Enough